Cargando…

Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far

Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interac...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales-Molina, José Antonio, Martínez-de la Plata, Juan Enrique, Urquízar-Rodríguez, Olivia, Molina-Arrebola, María Angustias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238480/
https://www.ncbi.nlm.nih.gov/pubmed/22184537
http://dx.doi.org/10.4081/hr.2011.e16
_version_ 1782219007979421696
author Morales-Molina, José Antonio
Martínez-de la Plata, Juan Enrique
Urquízar-Rodríguez, Olivia
Molina-Arrebola, María Angustias
author_facet Morales-Molina, José Antonio
Martínez-de la Plata, Juan Enrique
Urquízar-Rodríguez, Olivia
Molina-Arrebola, María Angustias
author_sort Morales-Molina, José Antonio
collection PubMed
description Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0–3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time.
format Online
Article
Text
id pubmed-3238480
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher PAGEPress Publications
record_format MEDLINE/PubMed
spelling pubmed-32384802011-12-19 Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far Morales-Molina, José Antonio Martínez-de la Plata, Juan Enrique Urquízar-Rodríguez, Olivia Molina-Arrebola, María Angustias Hematol Rep Case Report Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0–3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time. PAGEPress Publications 2011-10-10 /pmc/articles/PMC3238480/ /pubmed/22184537 http://dx.doi.org/10.4081/hr.2011.e16 Text en ©Copyright J.A. Morales-Molina, et al. 2011 This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Licensee PAGEPress, Italy
spellingShingle Case Report
Morales-Molina, José Antonio
Martínez-de la Plata, Juan Enrique
Urquízar-Rodríguez, Olivia
Molina-Arrebola, María Angustias
Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
title Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
title_full Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
title_fullStr Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
title_full_unstemmed Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
title_short Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
title_sort bosentan and oral anticoagulants in hiv patients: what we can learn of cases reported so far
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238480/
https://www.ncbi.nlm.nih.gov/pubmed/22184537
http://dx.doi.org/10.4081/hr.2011.e16
work_keys_str_mv AT moralesmolinajoseantonio bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar
AT martinezdelaplatajuanenrique bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar
AT urquizarrodriguezolivia bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar
AT molinaarrebolamariaangustias bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar